is an agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR) expressed on myeloid immune cells known to modulate inflammation.

Persistent inflammation is a characteristic feature of all chronic inflammatory or autoimmune diseases and if not controlled or resolved, it can lead to further tissue damage and give rise to tissue fibrosis with eventual loss of organ function. Most anti-inflammatory agents act using a mechanism that blocks pro-inflammation pathways. In contrast, OSE Immunotherapeutics is developing OSE-230 as a first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to complete the inflammation program and restore tissue integrity.

OSE Immunotherapeutics presented preclinical efficacy data on OSE-230 at the 2020 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting on October 29, 2020. These show that OSE-230 is the first monoclonal antibody triggering the activation of specialized receptors of resolution to restore tissue homeostasis, integrity and functions. These findings provide strong evidence for the therapeutic potential of OSE-230 to be developed in various chronic inflammation and autoimmune pathologies.

To receive OSE Immunotherapeutics’ latest news